Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users

AIDS

Volumn 27, Issue 16, 2013, Pages 2559-2566

  Westergaard, Ryan P ^a   Hess, Timothy ^a   Astemborski, Jacquie ^b   Mehta, Shruti H ^b   Kirk, Gregory D ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; drug users; human immunodeficiency virus; primary care; retention in care

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; VIRAL LOAD;

EID: 84885425011     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328363bff2     Document Type: Article

References (36)

1. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
2. Berg MB, Safren SA, Mimiaga MJ, Grasso C, Boswell S, Mayer KH. Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic. AIDS Care 2005; 17:902-907.
3. Giordano TP, Gifford AL, White AC Jr, Suarez-Almazor ME, Rabeneck L, Hartman C, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007; 44:1493-1499.
4. Mugavero MJ, Lin HY, Willig JH, Westfall AO, Ulett KB, Rout-man JS, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48:248-256.
5. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37:1112-1118.
6. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
7. Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338:b1649.
8. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
9. Giordano TP, Visnegarwala F, White AC Jr, Troisi CL, Frankowski RF, Hartman CM, et al. Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care 2005; 17:773-783.
10. Torian LV, Wiewel EW, Liu KL, Sackoff JE, Frieden TR. Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med 2008; 168:1181-1187.
11. Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA. For the HIVRN. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr 2012; 60: 249-259.
12. Arici C, Ripamonti D, Maggiolo F, Rizzi M, Finazzi MG, Pezzotti P, et al. Factors associated with the failure of HIVpositive persons to return for scheduled medical visits. HIV Clin Trials 2002; 3:52-57.
13. Schepens T, Morreel S, Florence E, Koole O, Colebunders R. Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS 2010; 21:765-769.
14. Lanoy E, Mary-Krause M, Tattevin P, Dray-Spira R, Duvivier C, Fischer P, et al. Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol 2006; 59: 829-835.
15. Torian LV, Wiewel EW. Continuity of HIV-related medical care, New York City, 2005-2009: do patients who initiate care stay in care? AIDS Patient Care STDS 2011; 25:79-88.
16. Mugavero MJ, Lin HY, Allison JJ, Giordano TP, Willig JH, Raper JL, et al. Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr 2009; 50:100-108.
17. Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA 2012; 308:339-342.
18. Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, et al. Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible hiv-infected individuals in North America, 2001-2009. Clin Infect Dis 2013; 56:1174-1182.
19. Krusi A, Wood E, Montaner J, Kerr T. Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy 2010; 21:4-9.
20. Vlahov D, Anthony JC, Munoz A, Margolick J, Nelson KE, Celentano DD. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr 1991; 109:75-100.
21. Centers for Disease C, Prevention. HIV infection among injection-drug users: 34 states, 2004- 2007. MMWR Morb Mortal Wkly Rep 2009; 58: 1291-1295.
22. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
23. Kavasery R, Galai N, Astemborski J, Lucas GM, Celentano DD, Kirk GD, et al. Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr 2009; 50:360-366.
24. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS 2010; 24:2665-2678.
25. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15:1707-1715.
26. Morris J, Golub E, Mehta S, Jacobson L, Gange S. Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther 2007; 4:12.
27. Mehta SH, Lucas G, Astemborski J, Kirk GD, Vlahov D, Galai N. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care 2007; 19:637-645.
28. Henrich TJ, Lauder N, Desai MM, Sofair AN. Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics. J Commun Health 2008; 33:69-77.
29. Hogg R, Samji H, Cescon A, Modur S, Napravnik S, Martin J, et al. Temporal changes in life expectancy of HIVR individuals: North America. Abstract #137. 19th Conference on Retro-viruses and Opportunistic Infections. Seattle2012.
30. Centers for Disease Control & Prevention. Vital signs: HIV prevention through care and treatment, United States. MMWR Morb Mortal Wkly Rep 2011; 60:1618-1623.
31. Moore RD, Bartlett JG. Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis 2011; 53:600-604.
32. Catz SL, McClure JB, Jones GN, Brantley PJ. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care 1999; 11:361-373.
33. Beach MC, Keruly J, Moore RD. Is the quality of the patientprovider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med 2006; 21:661-665.
34. Milloy MJ, Kerr T, Buxton J, Rhodes T, Krusi A, Guillemi S, et al. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2012; 59:393-399.
35. Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis 2011; 53:725-731.
36. Althoff KN, Buchacz K, Hall HI, Zhang J, Hanna DB, Rebeiro P, et al. U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med 2012; 157: 325-335.